Investigating the effect of Curcumin on Long Noncoding RNAs NUTM2A-AS1 and HCG18 expression changes in Hepatocellular Carcinoma (HCC) Curcumin on Hepatocellular Carcinoma (HCC)
Iranian Journal of Pharmaceutical Sciences,
Vol. 19 Núm. 4 (2023),
24 April 2024
,
Página 314-324
https://doi.org/10.22037/ijps.v19i4.43052
Resumen
Hepatocellular carcinoma (HCC) is a common tumor in liver tissue. The lack of molecular markers for the diagnosis and evaluation of treatment methods is noticeable despite the progression of HCC diagnostic and treatment methods; therefore, the present study aimed to find molecular markers with key roles in the initiation and progression of HCC and investigate the impact of curcumin on their expression. To this end, bioinformatics studies were conducted to candidate two long noncoding RNAs (lncRNAs) related to HCC, which interacted with the highest number of microRNAs (NUTM2A-AS1 and HCG18), and five microRNAs (hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-195-5p, and hsa-miR-424-5p), which interacted with most lncRNAs among candidate lncRNAs. Afterward, their expression was measured in hepG2 cancer cells and fibroblast cells treated with curcumin compared to the untreated samples. The expression of miRNAs and lncRNAs at half inhibition concentrations (IC50) of curcumin indicated that curcumin significantly increased the expression of miR-195, miR-15a/16, and miR-424 and reduced the expression of miR-15b-5P, NUTM2A-AS1 lncRNA, and HCG18 in comparison with a control group (P≤0.05). Obtained data showed that curcumin increases the expression of anti-cancer genes, miR-195, miR-15a/16, and miR-424, and decreases the activity of cancerous genes, miR-15b-5P, NUTM2A-AS1 lncRNA, and HCG18; therefore, it can be used as an anti-cancer agent in the treatment of HCC.
- Long noncoding RNAs (lncRNAs)
- Liver cancer
- Curcumin
Cómo citar
Citas
Wandeler G, Mauron E, Atkinson A, Dufour J-F, et al. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: relevance for screening strategies. (2019) 71 (2): 274-80.
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA oncology. (2018) 4 (11): 155-68.
Akinyemiju T, Abera S, Ahmed M, Alam N, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA oncology. (2017) 3 (12): 1683-91.
Stewart BW and Kleihues P. World cancer report. IARC press Lyon. (2003).
Le Grazie M, Biagini MR, Tarocchi M, Polvani S and Galli AJWjoh. Chemotherapy for hepatocellular carcinoma: The present and the future. (2017) 9 (21): 907.
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA and Pawlik TMJSo. Hepatocellular carcinoma: from diagnosis to treatment. (2016) 25 (2): 74-85.
Marquardt JU, Galle PR and Teufel AJJoh. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. (2012) 56 (1): 267-75.
Goudarzi M, Razeghi M, Chirani AS, Fazeli M, et al. Characteristics of methicillin-resistant Staphylococcus aureus carrying the toxic shock syndrome toxin gene: high prevalence of clonal complex 22 strains and the emergence of new spa types t223 and t605 in Iran. (2020) 36: 100695.
Zhang J and Lou WJFio. A key mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network linked to diagnosis and prognosis of hepatocellular carcinoma. (2020) 10: 340.
Ogunwobi OO, Harricharran T, Huaman J, Galuza A, et al. Mechanisms of hepatocellular carcinoma progression. (2019) 25 (19): 2279.
Si W, Shen J, Zheng H and Fan WJCe. The role and mechanisms of action of microRNAs in cancer drug resistance. (2019) 11 (1): 1-24.
Peng Y, Croce CMJSt and therapy t. The role of MicroRNAs in human cancer. (2016) 1 (1): 1-9.
Mai H, Zhou B, Liu L, Yang F, et al. Molecular pattern of lncRNAs in hepatocellular carcinoma. (2019) 38 (1): 1-15.
Sabet F, Mosavat A, Ghezeldasht SA, Basharkhah S, et al. Prevalence, genotypes and phylogenetic analysis of human papillomaviruses (HPV) in northeast Iran. (2021) 103: 480-8.
Serrano B, Brotons M, Bosch FX, Bruni LJBp, obstetrics rC and gynaecology. Epidemiology and burden of HPV-related disease. (2018) 47: 14-26.
Fazeli M, Soleimanjahi H and Dadashzadeh SJIjocp. Further stimulation of cellular immune responses through association of HPV-16 E6, E7 and L1 genes in order to produce more effective therapeutic DNA vaccines in cervical cancer model. (2015) 8 (1): 18.
Hayon T, Dvilansky A, Shpilberg O, Nathan IJL and lymphoma. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. (2003) 44 (11).
Jiang Z, Jin S, Yalowich JC, Brown KD and Rajasekaran B. The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Molecular cancer therapeutics. (2010) 9 (3): 558-68.
Tota JE, Isidean SD and Franco ELJIJoC. Defining benchmarks for tolerable risk thresholds in cancer screening: impact of HPV vaccination on the future of cervical cancer screening. (2020) 147 (12): 3305-12.
Elawad H. Sepsis and circulating miRNA: The road towards absolute quantification of unknown miRNA levels in plasma utilizing two-tailed RT-qPCR, while testing two extraction methods, striving to create multi-marker panel for sepsis diagnosis. In. (2021).
Torrejón D, Cárdenas J, Juárez D, Espinoza J, et al. Comparison of Four Methods of RNA Extraction and cDNA Synthesis from The Venom of Peruvian Snakes of the Genus Bothrops of Clinical Importance. (2023) 24 (13): 11161.
Aghamiri S, Talaei S, Roshanzamiri S, Zandsalimi F, et al. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert opinion on drug delivery. (2020) 17 (6): 753-66.
Hu C, Li M, Guo T, Wang S, et al. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT. (2019) 58: 152740.
Wang Y, Liang H, Jin F, Yan X, et al. Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway. (2019) 116 (13): 6162-71.
Zhang Y-J, Xiang H, Liu J-S, Li D, et al. Study on the mechanism of AMPK signaling pathway and its effect on apoptosis of human hepatocellular carcinoma SMMC-7721 cells by curcumin. (2017) 21 (5).
Goudarzi M, Kobayashi N, Hashemi A, Fazeli M, Navidinia MJOPH and Perspectives R. Genetic variability of methicillin resistant Staphylococcus aureus strains isolated from burns patients. (2019) 10 (3): 170.
Xu MX, Zhao L, Deng C, Yang L, et al. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway. (2013) 43 (6): 1951-9.
Hsu F-T, Liu Y-C, Liu T-T and Hwang J-JJBRI. Curcumin sensitizes hepatocellular carcinoma cells to radiation via suppression of radiation-induced NF-κB activity. (2015) 2015.
Kavoosi FJIJoPH and Oncology. Effect of curcumin and trichostatin a on the expression of DNA methyltransfrase 1 in hepatocellular carcinoma cell line hepa 1-6. (2018) 8 (4): 193-201.
Li Z, Zhu Z, Wang Y, Wang Y, et al. hsa‑miR‑15a‑5p inhibits colon cell carcinoma via targeting CCND1. (2021) 24 (4): 1-8.
Dong Y, Zhang N, Zhao S, Chen X, Li F and Tao XJOL. miR‑221‑3p and miR‑15b‑5p promote cell proliferation and invasion by targeting Axin2 in liver cancer. (2019) 18 (6): 6491-500.
Chen X, Wang AJO and therapy. Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression. (2019) 12: 527.
Zhang H, Yang K, Ren T, Huang Y, et al. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3. (2018) 9 (6): 680.
Piao L, Wang F, Wang Y, Yang Z, et al. Retracted: miR-424-5p regulates hepatoma cell proliferation and apoptosis. (2019) 34 (3): 196-202.
Li D, Tang X, Li M and Zheng YJJoCB. Long noncoding RNA DLX6‐AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR‐424‐5p. (2019) 120 (8): 12290-9.
Zhao Y, Zhu C, Chang Q, Peng P, et al. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7. (2020) 15 (11): e0242179.
Acha-Sagredo A, Uko B, Pantazi P, Bediaga NG, et al. Long noncoding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. (2020) 122 (7): 1050-8.
Zou Y, Sun Z and Sun SJTJoB. LncRNA HCG18 contributes to the progression of hepatocellular carcinoma via miR-214-3p/CENPM axis. (2020) 168 (5): 535-46.
Wang J, Zha J and Wang XJOL. Knockdown of lncRNA NUTM2A‑AS1 inhibits lung adenocarcinoma cell viability by regulating the miR‑590‑5p/METTL3 axis. (2021) 22 (5): 1-10.
Liu X, Qiao K, Zhu K, Li X, et al. Long Noncoding RNA HCG18 Promotes Malignant Phenotypes of Breast Cancer Cells via the HCG18/miR-103a-3p/UBE2O/mTORC1/HIF-1α–Positive Feedback Loop. (2021) 9: 675082.
- Resumen ##plugins.themes.ojsPlusA.frontend.article.viewed##: 139 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume19_Issue4_Pages314-324 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 61 ##plugins.themes.ojsPlusA.frontend.article.times##